The Pacific Northwest Udall Parkinson's Disease Center focuses on scientific and clinical research designed to gain a fuller understanding of the fundamental cause(s) of the disease, improve diagnosis, and develop new approaches to treatment.
Cognitive Function Assessments: Cognitive impairment is common in Parkinson's disease, is a significant source of disability for patients, and is associated with increased burden for caregivers. The primary research focus of PANUC is cognitive impairment in Parkinson's disease. We strive to understand the basis of this problem, and then through both clinical and basic research to discover new and better treatments for all patients with Parkinson's disease.
Genetic Research: Genetics plays an important role in susceptibility to Parkinson's disease. PANUC investigators are determining the role that genetics plays in cognitive impairment in Parkinson's disease and this will point us to new therapeutic targets.
Biomarker Testing: As we and others work on developing better treatments, it also will be necessary to develop tools to determine their effectiveness. PANUC biomarker research will address this problem by developing laboratory tests to estimate risk, aid in diagnosis, measure progression, and determine response to treatment of Parkinson's disease.
Experimental Medication Protocols: PANUC investigators will be seeking out novel treatment trials for Parkinson's disease and related disorders, particularly those related to cognitive impairment in Parkinson's disease.
National Institutes of Health (NIH)